Franklin Biotechnology has experienced managers, but limited supporting resources and a sensible yet undistinguished process limit its appeal.
Franklin Biotechnology Discovery Fund Class C FBTDX
- NAV / 1-Day Return 177.71 / −2.27 %
- Total Assets 1.2B
-
Adj. Expense Ratio
1.770%
- Expense Ratio 1.760%
- Distribution Fee Level Below Average
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 1.38%
- Turnover 22%
USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBTDX
Will FBTDX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 38.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Jazz Pharmaceuticals PLC | 6.30 | 67M | Healthcare |
Gilead Sciences Inc | 4.67 | 50M | Healthcare |
Amgen Inc | 4.50 | 48M | Healthcare |
Vertex Pharmaceuticals Inc | 4.11 | 44M | Healthcare |
argenx SE ADR | 3.85 | 41M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.53 | 38M | Healthcare |
Guardant Health Inc | 3.04 | 32M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.00 | 32M | Healthcare |
Ascendis Pharma AS | 2.74 | 29M | Healthcare |
Praxis Precision Medicines Inc Ordinary Shares | 2.52 | 27M | Healthcare |